Despite So-So Sales To Date, HGS Sees Promising Launch For Benlysta
Third quarter U.S. sales of $18.8 million disappoint some analysts, but HGS emphasizes growing patient base and multi-part commercialization plan still being implemented.
Third quarter U.S. sales of $18.8 million disappoint some analysts, but HGS emphasizes growing patient base and multi-part commercialization plan still being implemented.